Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Reply: Extramedullary relapse in high risk patients


Your e-mail address will only be available to administators.
X

Topic History of: Extramedullary relapse in high risk patients

Max. showing the last 6 posts - (Last post first)

  • Giuseppe Saglio
  • 's Avatar
10 years 9 months ago
Re: Extramedullary relapse in high risk patients

I think that he should be treated as an advanced phase. Please have a look at the mutations in the RNA extracted from the biopsy and, if you can, also at a cytogenetic analysis (but probably this is more difficult). Then I would probably introduce chemo + TKI if possible (according to the mutation analysis) and then eventually proceed to SCT as he is very young. If SCT transplant cannot be performed, maybe I would also consider radiation therapy on the involved lymphonodes But just to start, to obtain the mutation analysis is important.

  • B Moiraghi
  • 's Avatar
10 years 9 months ago
Extramedullary relapse in high risk patients

42 year old male with CML diagnosed in CF (since February 2012, Sokal high risk , he began treatment, with 2º G TKI Dasatinib 100 mg (Sprycel) At 6 months he was in CCR and MMR (IS) , he had mild adverse event, he never discontinued the treatment.
Since December 2012, he had cervical adenomegaly bilateral, a biopsy was made in May 2013 (he was in HR, CCR and MMR)the adenopaty biopsy is CML (Granulocitic Sarcoma), pending the inmunofenotype.
The patient was in good perfomance
Any feedback regarding treatment would be much appreciated.
Thanks